Abstract:Adenosine is an endogenous nucleoside with a short half-life that regulates many physiological functions involving the heart and cardiovascular system. Among the cardioprotective properties of adenosine are its ability to improve cholesterol homeostasis, impact platelet aggregation and inhibit the inflammatory response. Through modulation of forward and reverse cholesterol transport pathways, adenosine can improve cholesterol balance and thereby protect macrophages from lipid overload and foam cell transformation. The function of adenosine is controlled through four G-protein coupled receptors: A1, A2A, A2B and A3. Of these four, it is the A2A receptor that is in a large part responsible for the anti-inflammatory effects of adenosine as well as defense against excess cholesterol accumulation. A2A receptor agonists are the focus of efforts by the pharmaceutical industry to develop new cardiovascular therapies, and pharmacological actions of the atheroprotective and anti-inflammatory drug methotrexate are mediated via release of adenosine and activation of the A2A receptor. Also relevant are anti-platelet agents that decrease platelet activation and adhesion and reduce thrombotic occlusion of atherosclerotic arteries by antagonizing adenosine diphosphate-mediated effects on the P2Y12 receptor. The purpose of this review is to discuss the effects of adenosine on cell types found in the arterial wall that are involved in atherosclerosis, to describe use of adenosine and its receptor ligands to limit excess cholesterol accumulation and to explore clinically applied anti-platelet effects. Its impact on electrophysiology and use as a clinical treatment for myocardial preservation during infarct will also be covered. Results of cell culture studies, animal experiments and human clinical trials are presented. Finally, we highlight future directions of research in the application of adenosine as an approach to improving outcomes in persons with cardiovascular disease.

Adenosine and adenosine receptor-mediated action in coronary microcirculation

Adenosine signaling: good or bad in erectile function?

Detrimental Effects of Adenosine Signaling in Sickle Cell Disease

Increased Endogenous Adenosine Production in Penile Tissues in Response to Cavernosal Nerve Stimulation

Adenosine and the Cardiovascular System

Physiopathologic and Pharmacologic Effects in Coronary Artery Disease

Adenosine Deaminase Acting on RNA 1 (ADAR1) As Crucial Regulators in Cardiovascular Diseases: Structures, Pathogenesis, and Potential Therapeutic Approach

Beneficial and Detrimental Role of Adenosine Signaling in Diseases and Therapy.

Historical and Current Adenosine Receptor Agonists in Preclinical and Clinical Development

Adenosine and the Cardiovascular System: The Good and the Bad

Drugs targeting adenosine signaling pathways: A current view

Adenosine in the airways: implications and applications

In vivo assessment of coronary flow and cardiac function after bolus adenosine injection in adenosine receptor knockout mice

Pharmacology and Therapeutic Applications of A1 Adenosine Receptor Ligands

Adenosine signaling in diabetes mellitus and associated cardiovascular and renal complications

Abstract 12514: Elevated Intracellular Adenosine Epigenetically Regulates Endothelial Inflammation <i>(Best of Basic Science Abstract)</i>

From Molecular Signaling to Therapeutic Strategies for Heart Diseases

Progress in the pursuit of therapeutic adenosine receptor antagonists

Cell-signaling Evidence for Adenosine Stimulation of Coronary Smooth Muscle Proliferation Via the A1 Adenosine Receptor.

A2B adenosine receptor signaling and regulation

Adenosine and adenosine receptors in metabolic imbalance-related neurological issues